Breaking News in Spinal Cord Injury Research FDA Approved Phase I Clinical Trial of Human, Autologous Schwann Cell Transplantation in Patients with Spinal Cord Injuries

Xiao-Ming Xu

首页> 中文期刊> 《中国神经再生研究：英文版》 >Breaking News in Spinal Cord Injury Research FDA Approved Phase I Clinical Trial of Human, Autologous Schwann Cell Transplantation in Patients with Spinal Cord Injuries

Breaking News in Spinal Cord Injury Research FDA Approved Phase I Clinical Trial of Human, Autologous Schwann Cell Transplantation in Patients with Spinal Cord Injuries

开具论文收录证明 >>

期刊封面封底目录下载 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

On July 31, 2012, The Miami Project to Cure Paralysis at the University of Miami Miller School of Medicine received permission from the Food and Drug Administration (FDA) to begin a Phase I clinical trial to evaluate the safety of transplanting human autologous Schwann cells to treat patients with spinal cord injuries.This is the only FDA-approved cell therapy-based clinical trial for sub-acute spinal cord injury in the United States.

著录项

来源
《中国神经再生研究：英文版》 |2012年第22期|1685-1687|共3页
作者
Xiao-Ming Xu;
展开▼
作者单位

Spinal Cord and Brain Injury Research Group;

Stark Neurosciences Research Institute & Department of Neurological Surgery;

IndianaUniversity School of Medicine;

Indianapolis;

IN 46202;

USA;

展开▼
原文格式 PDF
正文语种 chi
中图分类外伤外科学;鸡;
关键词
急性脊髓损伤; 临床试验; 细胞移植; FDA; 患者; 自体; 新闻; 细胞治疗;

相似文献

中文文献
外文文献

Breaking News in Spinal Cord Injury Research FDA Approved Phase I Clinical Trial of Human, Autologous Schwann Cell Transplantation in Patients with Spinal Cord Injuries

摘要

著录项

相似文献

相关主题

期刊订阅